Meningococcal Vaccines: Current Status and Emerging Strategies

Vaccines — Open Access Journal
(Accessed 3 March 2018)

Open Access Review
Meningococcal Vaccines: Current Status and Emerging Strategies
by Pumtiwitt C. McCarthy, Abeer Sharyan and Laleh Sheikhi Moghaddam
Vaccines 2018, 6(1), 12; doi:10.3390/vaccines6010012 – 25 February 2018
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against N. meningitidis in the future